Northwest Biotherapeutics inc  (NWBO)
Other Ticker:  
Price: $0.5788 $-0.01 -1.481%
Day's High: $0.599 Week Perf: 6.99 %
Day's Low: $ 0.56 30 Day Perf: -1.23 %
Volume (M): 985 52 Wk High: $ 1.01
Volume (M$): $ 570 52 Wk Avg: $0.64
Open: $0.59 52 Wk Low: $0.40

 Market Capitalization (Millions $) 553
 Shares Outstanding (Millions) 955
 Employees 16
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -73
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 6

Northwest Biotherapeutics Inc
Northwest Biotherapeutics, Inc. is a clinical-stage biotechnology company based in Bethesda, Maryland, that specializes in developing personalized immunotherapy products for the treatment of cancer. The company's focus is on developing and commercializing novel cancer therapies based on its DCVax platform technology, which involves using dendritic cells to stimulate the body's immune system to fight cancer.

DCVax is a unique personalized immunotherapy platform that involves extracting dendritic cells from a patient's blood and then exposing them to tumor antigens in order to activate the immune system's T-cells to attack the cancer. The activated dendritic cells are then injected back into the patient to stimulate an immune response against the cancer.

The company has several clinical trials underway for its DCVax products, including:

- DCVax-L for glioblastoma multiforme (GBM), a deadly form of brain cancer that has limited treatment options. The Phase III trial for this product has completed enrollment and awaits data analysis.
- DCVax-Direct for all solid tumor cancers, which involves injecting activated dendritic cells directly into tumors. This product is currently in Phase I/II trials.
- DCVax-Prostate for prostate cancer, which is in Phase II trials.

Northwest Biotherapeutics has also developed a specialized manufacturing facility for the production of its personalized immunotherapy products, which has received approval from the U.S. Food and Drug Administration (FDA). The company's manufacturing process is designed to ensure consistency and quality in the production of its DCVax products.

In addition to its DCVax products, Northwest Biotherapeutics is also developing other cancer therapies, including:

- Allo-528, a monoclonal antibody for the treatment of acute leukemia and other hematologic malignancies. This product is currently in preclinical development.
- DCVax-L-NG for pediatric brain cancer, which is also currently in preclinical development.

Northwest Biotherapeutics has received several grants and awards for its innovative cancer research and development, including from the National Cancer Institute and the European Union. The company has also received funding from investors, including institutional investors, to support its clinical trials and operations.

In summary, Northwest Biotherapeutics is a clinical-stage biotechnology company focused on developing personalized cancer immunotherapy products using its DCVax platform technology. The company has several clinical trials underway for its DCVax products and has also developed a specialized manufacturing facility for their production. In addition, Northwest Biotherapeutics is developing other cancer therapies, and has received grants and funding to support its research and development efforts.

   Company Address: 4800 Montgomery Lane Bethesda 20814 MD
   Company Phone Number: 497-9024   Stock Exchange / Ticker: NONE NWBO


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Northwest Biotherapeutics Inc

NWBO's July to September 2023 Findings Reveal Fascinating Results

Northwest Biotherapeutics Inc (NWBO) recently released its financial results for the fiscal interval ending September 30, 2023, showcasing positive developments in their revenue and net deficit compared to the previous year. Despite ongoing challenges faced by the Major Pharmaceutical Preparations industry, NWBO's results have exceeded expectations, leading to a rise in the company's stock value.
Financial Results:
NWBO reported a loss of $-0.02 per share for the fiscal period ending September 30, 2023, compared to a loss of $-0.03 per share during the same quarter a year ago. This indicates an improvement in profitability. Furthermore, NWBO's deficit grew from $-0.01 per share in the prior quarter. Although the deficit increased, the decrease in the loss per share is a positive outcome.

Northwest Biotherapeutics Inc

Northwest Biotherapeutics Inc's Q2 2023 Earnings: A Mix of Positive and Stable Results

The stock market is a dynamic and often unpredictable environment, where quarterly financial reports can make or break investment decisions. In the case of Northwest Biotherapeutics Inc, the second quarter of 2023 earnings season has shown mixed results. Let's delve deeper into the figures and assess what they mean for the company and its investors.
Earnings per Share:
Northwest Biotherapeutics Inc experienced both positive and negative developments in its earnings per share (EPS) during the second quarter of 2023. While its loss per share improves significantly from $-0.03 to $-0.01 compared to the previous year, it remains unchanged from the previous quarter. This stabilization in losses shows a level of consistency, which could be interpreted as a positive sign by investors.

Northwest Biotherapeutics Inc

Northwest Biotherapeutics Inc Shocks Market with Exceptional Revenue Surge in Q1 2023

Northwest Biotherapeutics Inc, a clinical-stage biotechnology company, has reported a significant surge in its revenue for the financial time-frame ending March 31, 2023. According to the company's latest financial results, Northwest Biotherapeutics Inc's revenue rose by a remarkable 118.362% year on year to a value of $0.88 million. This marks an impressive milestone for the company, as it indicates strong growth in its business operations over the past year.
However, despite the impressive growth in revenue, Northwest Biotherapeutics Inc's net loss for the first quarter of 2023 was reported at $-11.047 million. This is a considerable improvement from a deficit of $-14.214 million in the previous reporting season. Moreover, the company's loss per share remained constant at $-0.01.


Northwest Biotherapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com